Prior efforts to image cholinergic projections in human brain in vivo had significant technical limitations. We used the vesicular acetylcholine transporter (VAChT) ligand [ 
neurons. BF cholinergic pathways participate in the modulation of important cognitive functions such as attention and executive function (Ballinger, Ananth, Talmage, & Role, 2016; Hasselmo & Sarter, 2011; . Projections of the PPN-LDT complex may play important roles in the regulation of sleep and waking, and some data implicates these neurons in control of balance and gait (Gut & Winn, 2016; Mena-Segovia & Bolam, 2017; Pienaar, Vernon, & Winn, 2016) . Striatal cholinergic interneurons are the subject of intense investigations and play important roles in the control of a variety of functions mediated by the striatal complex (Deffains & Bergman, 2015; Gonzales & Smith, 2015; Tanimura et al., 2017) .
Abnormalities of some of these pathways are implicated in neurologic and psychiatric disease, particularly Alzheimer disease (AD), Parkinson disease (PD), and tobacco abuse. Degeneration of the BF complex is documented well in AD and PD, and degeneration of cholinergic PPN-LDT neurons may drive important aspects of declining gait and balance functions in PD and Progressive Supranuclear Palsy (Bohnen et al., 2012; Gilman et al., 2010; Hirsch, Graybiel, Duyckaerts, & Javoy-Agid, 1987; Mesulam, 2013; Mufson, Ginsberg, Ikonomovic, & DeKosky, 2003; Schliebs & Arendt, 2011) . Augmenting cholinergic neurotransmission with acetylcholinesterase inhibitors is an accepted treatment for dementias, including AD, Lewy body dementia, and PD-associated dementia. Anti-muscarinic cholinergic agents are used for the treatment of dystonias and for treatment of PD-associated tremor. Manipulations of cholinergic neurotransmission are being pursued to improve gait and balance functions in PD (Chung, Lobb, Nutt, & Horak, 2010; Henderson et al., 2016; Kucinski, De Jong, & Sarter, 2017; Li et al., 2015) . Nicotinic cholinergic receptors mediate the addictive effects of nicotine and drugs active at this receptor family are used to treat nicotine addiction (Anthenelli et al., 2016) . Improved understanding of the organization of cholinergic pathways in the human brain is relevant to efforts to expand useful cholinergic pharmacology in the treatment of human neurologic and psychiatric diseases.
Prior investigations in other species, including nonhuman primates, and work with postmortem human tissues provided considerable information about the organization of human brain cholinergic pathways (Albin, Morgan, Higgins, & Frey, 1994; Barmack, Baughman, Eckenstein, & Shojaku, 1992; de Lacalle et al., 1994; De Lacalle, Hersh, & Saper, 1993; Emre, Heckers, Mash, Geula, & Mesulam, 1993; Fitzpatrick, Diamond, & Raczkowski, 1989; Fukushima et al., 2001; Gilmor et al., 1996 Gilmor et al., , 1999 Heckers, Geula, & Mesulam, 1992; Ichikawa, Ajiki, Matsuura, & Misawa, 1997; Jaarsma et al., 1997; Kus et al., 2003; Levey, Hallanger, & Wainer, 1987; Mahady, Perez, Emerich, Wahlberg, & Mufson, 2017; Manaye et al., 1999; Mesulam, 2004; Mesulam & Geula, 1988; Mesulam, Geula, Bothwell, & Hersh, 1989; Mesulam, Mash, Hersh, Bothwell, & Geula, 1992; Roghani, Shirzadi, Butcher, & Edwards, 1998; Schäfer, Eiden, & Weihe, 1998; Schafer, Weihe, Erickson, & Eiden, 1995; Woolf, 1991; Woolf & Butcher, 1985 , 1986 Woolf, Eckenstein, & Butcher, 1984; Zhang, Zhou, & Yuan, 2016) . Working with postmortem tissues has intrinsic limitations and inferences from studies of other species may be confounded by inter-species differences.
To advance our understanding of the organization of cholinergic pathways in humans, we assessed the regional distribution of human brain cholinergic neuron terminals with [ Petrou et al., 2014) . FEOBV is a high-affinity ligand for the vesicular acetylcholine transporter (VAChT), the protein responsible for pumping ACh from the cytosol into synaptic vesicles Prado, Roy, Kolisnyk, Gros, & Prado, 2013) . VAChT is expressed at uniquely high levels by cholinergic neurons (Arvidsson, Riedl, Elde, & Meister, 1997) . Prior human imaging studies of brain VAChT expression used less resolute single photon emission computed tomography (SPECT) methods (Kuhl et al., 1994 (Kuhl et al., , 1996 Lamare et al., 2013) . Prior PET studies of regional cholinergic terminal distribution used acetylcholinesterase (AChase) substrates ([ [MP4A]) to identify cholinergic synapses (Iyo et al., 1997; Kuhl et al., 1999) . These methods are less specific. AChase, for example, is produced by midbrain dopaminergic neurons and high regional AChase activity was detected in regions, the lateral cerebellar cortices, not suspected to have substantial cholinergic terminal innervation (Greenfield, 1991; Kuhl et al., 1999) . AChase enzyme activity may be regulated by synaptic activity and disease states, a potential obstacle to quantifying regional cholinergic terminal density (DeKosky et al., 1992) . The very high AChase expression characteristic of the striatum limits quantification of striatal AChase as PMP and MP4A metabolite accumulation may be flow, rather than AChase activity, limited. PMP and MP4A are also, though to a considerably lesser extent, butyrylcholinesterase substrates and butyrylcholinesterase activity changes might influence the results of PET studies with these tracers (Snyder et al., 2001 ).
We describe the regional distribution of [ 
| METHODS

| Subjects
We studied 29 subjects without histories of the neurologic or psychiatric disease. We studied 18 men and 11 women. The mean age was 47 years (SD = 21 years); age range 20-81 years. No subject was using a medication that might affect cholinergic neurotransmission and none were using tobacco or nicotine products. Informed consent was obtained from all subjects prior to study entry and this study was approved by the University of Michigan Medical School IRB. Limited results were reported previously from subsets of these subjects (Albin, Minderovic, & Koeppe, 2017; Petrou et al., 2014 tively. This was done to allow the creation of mean images of all subjects, plus mean images for young and elderly cohorts, and to allow better visualization of effects of aging. We also used our standard VOI set developed for Talairach space, which is based entirely on the PET scans (no MR), as described previously (Bohnen et al., 2006) . Brainstem parcellation was performed as described previously (Albin et al., 2008 
| Aging effects
To assess potential aging effects, we took advantage of the fact that our study population was divided into two groups; a younger group (N = 13; Mean 25 years; range 20-38) and an older group (N = 16;
Mean 66 years; range 52-81). Inspection of averaged images for these groups suggested regionally specific age-related declines in Table 1 ). Binding was highest in the striatal complex, followed by portions of the thalamus, amygdala and hippocampal formation, some neocortical regions, rostral brainstem, and some regions of the cerebellar cortex. The overall distribution and regional density of [
| Statistical analysis
FEOBV binding is largely consistent with the distribution of cholinergic terminals described in prior human postmortem and nonhuman mammal studies (Albin et al., 1994; Barmack, Baughman, Eckenstein, & Shojaku, 1992 Mahady et al., 2017; Manaye et al., 1999; Mesulam, 2004; Mesulam et al., 1989; Mesulam & Geula, 1988; Roghani et al., 1998; Schafer et al., 1995; Schäfer et al., 1998; Woolf, 1991; Woolf et al., 1984; Woolf & Butcher, 1985 , 1986 Zhang et al., 2016) . Our results are consistent as well with prior VAChT ligand human SPECT imaging studies (Kuhl et al., 1994 (Kuhl et al., , 1996 Lamare et al., 2013) . Figure 3 ). (Figures 1 and 6 ).
| Striatal complex
| Thalamus
| Aging effects
Potential aging effects were assessed initially by comparing younger (22-38 years) and older (52-81 years) subjects. These comparisons revealed regionally specific changes accompanying aging ( (Table 3) . There was no evidence of age-related decline in the cerebellar vermis and other cortical regions (Table 3) . To further explore the relationship between aging and regional [ 
| DISCUSSION
VAChT is thought to be uniquely expressed by cholinergic neurons. The
VAChT gene is part of a distinctive cholinergic "operon," encoded within the first exon of the Choline Acetyltransferase gene (Eiden, 1998) . FEOBV is a high affinity and specific ligand for VAChT (Mulholland et al., 1998) . In general, our findings correlate well with prior studies of brain cholinergic systems in humans and other mammals based on ChAT and high-affinity choline transporter immunohistochemistry (Kus et al., 2003; and see below) . Our results also correlate well with nonhuman animal and limited human studies of the distribution of brain VAChT immunoreactivity (Arvidsson et al., 1997; Gilmor et al., 1996 Gilmor et al., , 1999 Ichikawa et al., 1997; Roghani et al., 1998; Schafer et al., 1995; Schäfer et al., 1998 (Aghourian et al., 2017; Albin et al., 2017; Petrou et al., 2014) .
| Striatal complex
The striatal complex exhibited the highest regional [ 18 F]FEOBV binding, indicating a very high density of cholinergic terminals within the striatal complex. This result is consistent with a large body of data from studies in many species indicating uniquely high expression of cholinergic system markers and terminals in the striatal complex.
There are at least two, and possibly three, sources of striatal cholinergic terminals. While striatal cholinergic interneurons comprise only a small fraction (~2-3%) of the total striatal neuron population (Bernácer, Prensa, & Giménez-Amaya, 2007; Gonzales & Smith, 2015;  Lecumberri, Lopez-Janeiro, Corral-Domenge, & Bernacer, 2018) they give rise to dense axonal-terminal arborizations and play an important role in the integration of cortico-and thalamo-striate inputs with dopaminergic functions. The striatal complex also receives innervation from mesopontine (PPN-LDT) cholinergic neurons (Dautan et al., 2014; Dautan, Hacio glu Bay, Bolam, Gerdjikov, & Mena-Segovia, 2016; Woolf, 1991) , presumably collaterals of neurons innervating the thalamus and other targets of the PPN-LDT complex. suggested that the human striatal complex receives some cholinergic afferents from the basal forebrain complex, a projection that is absent in rodents (Dautan et al., 2016) . The relative proportion of striatal cholinergic interneuron terminals and extrinsic afferent terminals is unknown. It is generally assumed that striatal cholinergic interneuron terminals are much more abundant than extrinsic cholinergic afferent terminals. Janickova et al. (2017) suggested that human cholinergic basal forebrain projections to the striatal complex more heavily innervate the putamen.
| Cortex
The cortical mantle receives its cholinergic inputs from cholinergic neurons of the basal forebrain complex (Ch1-Ch4 in the Mesulam, Mufson, Wainer, & Levey, 1983) . These cholinergic projections are known to participate in several important cognitive processes including attention, executive functions, and forms of memory (Ballinger et al., 2016; Hasselmo & Sarter, 2011; Prado et al., 2017) . Our results are broadly consistent with data from older analyses of cholinergic terminal markers in human postmortem specimens (de Lacalle et al., 1994; Emre et al., 1993; Mesulam, 2004 Mesulam, , 2013 Mesulam & Geula, 1988; . Consistent with these prior descriptions, highest [ 18 F]FEOBV binding was found in amygdala and hippocampal formation, followed by paralimbic cortices, including the insular cortex, perirhinal cortex (BA35), entorhinal cortex (BA34, BA28), parahippocampal gyrus (BA27), and portions of the cingulate cortex (BA25, BA24). Regional binding density is probably not the only important difference in cholinergic innervation between cortical regions. also described varying laminar distributions of cholinergic terminals between neocortical regions. Detecting such differences is beyond the resolution of PET imaging. Similarly, prior studies indicate that the basolateral amygdala exhibits the highest density of cholinergic terminals with other amygdala nuclei exhibiting significantly less cholinergic innervation (Emre et al., 1993) .
| Thalamus
Analysis of the thalamus was limited by lack of an accepted parcellation method for thalamic subnuclei. Nonetheless, our data suggest significant inhomogeneity for [ Our results are consistent with the work of Heckers et al. (1992) assessing cholinergic terminal density with ChAT immunohistochemistry in human postmortem specimens. Heckers et al. (1992) documented ChAT immunoreactive fibers throughout the human thalamus with the greatest density of ChAT-immunoreactive fibers in the lateral geniculate nuclei, some intralaminar nuclei, the reunions nucleus, the anterodorsal nucleus, the reticular nucleus, and some portions of the mediodorsal nucleus. Lowest density of ChAT-immunoreactive fibers was seen in the pulvinar and medial geniculate nuclei. As Heckers et al. (1992) point out the human subregional distribution of thalamic cholinergic terminals is likely distinct from that found in the limited number of other species studied (Fitzpatrick et al., 1989; Levey et al., 1987) . (Heckers et al., 1992) .
Cholinergic afferents to the thalamus are implicated in several important phenomena, notably the regulation of consciousness and sleep, though the abundance of cholinergic terminals and receptors within the thalamus suggests cholinergic neurotransmission may modulate multiple aspects of thalamic function. Recent work, for example, from our group suggests that thalamic cholinergic neurotransmission contributes to "bottom-up" detection of salient sensory cues (Kim, Müller, Bohnen, Sarter, & Lustig, 2017) .
| Cerebellum
Prior work in several species suggests significant cholinergic innervation of some cerebellar regions Barmack, Baughman, Eckenstein, & Shojaku, 1992; de Lacalle et al., 1993; Fukushima et al., 2001; Jaarsma et al., 1997; Manaye et al., 1999; Zhang et al., 2016) . There is no evidence of cholinergic neurons within the cerebellum in most species studied. Cholinergic terminals were detected throughout the cerebellar cortex, though most studies describe these as relatively sparse in most cerebellar cortical regions. [ Barmack, Baughman, Eckenstein, & Shojaku, 1992) described relatively high levels of cholinergic innervation of some cerebellar cortical regions in rat, rabbit, car, and nonhuman primate brain. These included the uvula-nodulus (lobules 9 and 10), the floccular region, and the anterior vermis (lobules 1 and 2) Barmack, Baughman, Eckenstein, & Shojaku, 1992) . The predominant source of these terminals appears to be cholinergic neurons of the vestibular complex. Jaarsma et al. (1997) (Gielow & Zaborszky, 2017) , our results suggest inhomogeneous age-related changes within the BF complex. Prior SPECT studies of human VAChT distribution also suggested age-related decline in BF corticopetal terminals but lacked the precision to resolve changes in individual neocortical regions (Kuhl et al., 1996) .
| Aging effects
4.7 | General conclusion FEOBV PET is likely to be a useful method for studying disease states, including several neurodegenerative disorders and psychiatric disorders.
